These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18574994)

  • 1. [Treatment with intravenous immunoglobulin in neurological diseases. A descriptive study of effects seen from the patient's and health services' perspectives].
    Wintzell A; Eriksson T; Lundgren A; Petersson J
    Lakartidningen; 2008 May 21-27; 105(21):1571-5. PubMed ID: 18574994
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in the use of IVIg in neurological disorders.
    Hughes R
    J Neurol; 2008 Jul; 255 Suppl 3():1-2. PubMed ID: 18685918
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous immunoglobulin treatment in autoimmune neurological disorders--effects on quality of life.
    Padua L; Sabatelli M; Evoli A; Pazzaglia C; Tonali P
    Hum Immunol; 2005 Apr; 66(4):417-21. PubMed ID: 15866706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study.
    Stangel M; Kiefer R; Pette M; Smolka MN; Marx P; Gold R
    J Neurol; 2003 Jul; 250(7):818-21. PubMed ID: 12883923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of immunoglobulin in the therapy of neurological illnesses].
    Elovaara I; Färkkilä M; Hietaharju A; Pirttilä T
    Duodecim; 2001; 117(10):1033-41; quiz 1041, 1081. PubMed ID: 12116461
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous immunoglobulins in neurological diseases.
    Zettl UK; Mix E
    J Neurol; 2006 Sep; 253 Suppl 5():V1. PubMed ID: 16998748
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacoeconomics of intravenous immunoglobulin in various neurological disorders.
    Tsai CP
    Acta Neurol Taiwan; 2010 Dec; 19(4):303-8. PubMed ID: 21234830
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
    Rigas M; Tandan R; Sterling RJ
    J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunomodulator effects of intravenous immunoglobulins in neurological autoimmune diseases].
    Mouthon L; Kaveri SV; Kazatchkine MD
    Rev Neurol (Paris); 1995 Feb; 151(2):91-2. PubMed ID: 7676148
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous immune globulin in autoimmune and inflammatory diseases.
    Gelfand EW
    N Engl J Med; 2012 Nov; 367(21):2015-25. PubMed ID: 23171098
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prospective study of side effects of intravenous immunoglobulins in neurological diseases].
    Faucheux JM; Bille-Turc F; Pouget J; Serratrice G
    Presse Med; 1994 Apr; 23(14):673. PubMed ID: 8072970
    [No Abstract]   [Full Text] [Related]  

  • 12. A practical approach to the use of intravenous immunoglobulin in neurological disease.
    Wills AJ; Unsworth DJ
    Eur Neurol; 1998; 39(1):3-8. PubMed ID: 9476717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin therapy in neurological diseases during pregnancy.
    Ringel I; Zettl UK
    J Neurol; 2006 Sep; 253 Suppl 5():V70-4. PubMed ID: 16998758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current indications of polyvalent immunoglobulins].
    Magy L
    Bull Acad Natl Med; 2012 Jan; 196(1):49-60; discussion 61. PubMed ID: 23259332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommended indications for the administration of polyclonal immunoglobulin preparations.
    Delforge M; Farber CM; Spath P; Kaveri S; Witte T; Misbah SA; Hübner R; Haerynck F; Latinne D; Muylle L; Toungouz M; Deneys V;
    Acta Clin Belg; 2011; 66(5):346-60. PubMed ID: 22145269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.
    Rey JB; Luria RB
    J Am Acad Dermatol; 2009 Jun; 60(6):1037-41. PubMed ID: 19249127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of intravenous immunoglobulins in Belgium.
    Simoens S
    Int Arch Allergy Immunol; 2011; 154(2):173-6. PubMed ID: 20733326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin (IVIG).
    Med Lett Drugs Ther; 2006 Dec; 48(1249/1250):101-3. PubMed ID: 17149360
    [No Abstract]   [Full Text] [Related]  

  • 19. [Good response of scleromyxedema and dermato-neuro syndrome to treatment with intravenous immunoglobulins].
    Bielsa I; Benvenutti F; Guinovart RM; Ferrándiz C
    Actas Dermosifiliogr; 2012 May; 103(4):317-20. PubMed ID: 21917233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.